Eukaryotic Cell Patents (Class 424/93.21)
  • Patent number: 10738313
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: August 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10738312
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: August 11, 2020
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10736918
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 11, 2020
    Assignees: Fred Hutchinson Cancer Research Center, Seattle Children's Hospital
    Inventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
  • Patent number: 10736919
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: August 11, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 10729789
    Abstract: The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 4, 2020
    Assignee: University of Virginia Patent Foundation
    Inventor: Brent A. French
  • Patent number: 10729725
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 4, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 10724038
    Abstract: An in vitro method to discover or screen various an agent capable of modulating onset or progression of hepatic metastasis through inhibition or suppression of genes associated with prometastatic reaction in hepatic tissue. The method comprises preparing a primary mix-culture of hepatic parenchymal and non-parenchymal cells, exposing cells to colorectal cancer cells to induce a prometastatic reaction; the exposing the cells to the therapeutic agent to be screened, and then measuring gene expression profiles of cells exposed to the agent, and finally comparing the measured gene expression profile to a reference gene expression profile whereby to determine if the agent has a positive effect on inhibiting or suppressing metastatic reaction.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 28, 2020
    Assignee: Persona Biomed, Inc.
    Inventor: Fernando Vidal-Vanaclocha
  • Patent number: 10716814
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: July 21, 2020
    Assignee: Mesoblast International Sàrl
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 10717993
    Abstract: Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: July 21, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Gary Ka Leong Lee
  • Patent number: 10709739
    Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 14, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
  • Patent number: 10703794
    Abstract: An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and (g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 7, 2020
    Assignee: King's College London
    Inventors: John Maher, Daniela Yordanova Achkova, Lynsey May Whilding, Benjamin Owen Draper
  • Patent number: 10696948
    Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin ?2?1?1, laminin ?2?2?1, laminin ?1?1?1 and laminin ?1?2?1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: June 30, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Yukiko Ochi, Kiyotoshi Sekiguchi, Shigeru Miyagawa, Yoshiki Sawa, Antti Markus Siltanen
  • Patent number: 10696973
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Patent number: 10688136
    Abstract: Compositions and methods are provided for induction and maintenance of quiescence of stem cells.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: June 23, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Marco Quarta, Thomas A. Rando
  • Patent number: 10689456
    Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 23, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Qiong J. Wang, Zhiya Yu, James C. Yang
  • Patent number: 10689431
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 23, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Patent number: 10676717
    Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13R?2 (IL13R?2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 9, 2020
    Assignee: City of Hope
    Inventors: Christine E. Brown, Stephen J. Forman
  • Patent number: 10669547
    Abstract: The invention provides compositions and methods of making and using effector oligonucleotides, including effector oligonucleotides with greater than one mismatch as compared to its target sequence. These effector oligonucleotides are useful for improving the efficiency of genomic editing as well as providing therapeutic benefits to individuals in need thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 2, 2020
    Inventor: Kambiz Shekdar
  • Patent number: 10668101
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: June 2, 2020
    Assignee: MESOBLAST INTERNATIONAL SÁRL
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 10670582
    Abstract: Described are methods and compositions for increasing islet-1 (Isl1) activity (e.g., biological activity) and or expression (e.g., transcription and/or translation) in a biological cell and or in a subject.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: June 2, 2020
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Mingqian Huang, Albena Kantardzhieva, Zheng-Yi Chen
  • Patent number: 10669596
    Abstract: The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: June 2, 2020
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Tamer M. A. Mohamed, Deepak Srivastava
  • Patent number: 10660917
    Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 26, 2020
    Assignee: Maxcyte, Inc.
    Inventors: Linhong Li, Madhusudan V. Peshwa
  • Patent number: 10654907
    Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: May 19, 2020
    Assignee: University Health Network
    Inventors: Naoto Hirano, Munehide Nakatsugawa, Toshiki Ochi
  • Patent number: 10647999
    Abstract: The present invention relates to nucleic acid molecules which are capable of promoting transcription of operably-linked heterologous polynucleotides in mammalian cells. The invention also relates to expression vectors and host cells which comprise the nucleic acid molecules of the invention. Such expression vectors may be used to produce recombinant proteins, e.g. antibodies and lentiviral polypeptides.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: May 12, 2020
    Assignee: Oxford Genetics Limited
    Inventors: Ryan Cawood, Richard Parker-Manuel, Weiheng Su
  • Patent number: 10640771
    Abstract: Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: May 5, 2020
    Assignees: GENZYME CORPORATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE
    Inventors: Samuel Wadsworth, Abraham Scaria, Chi-Chao Chan
  • Patent number: 10632212
    Abstract: The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 28, 2020
    Assignees: bluebird bio, Inc., Massachusetts Institute of Technology
    Inventors: Philippe Louis Leboulch, Robert Pawliuk, Karen Westerman
  • Patent number: 10617721
    Abstract: A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: April 14, 2020
    Assignees: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE TELETHON
    Inventors: Luigi Naldini, Bernhard Rudolf Gentner, Erika Zonari, Francesco Boccalatte
  • Patent number: 10618945
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 14, 2020
    Assignee: Immatics Biotechnologies GMBH
    Inventor: Jorn Dengjel
  • Patent number: 10610545
    Abstract: Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: April 7, 2020
    Assignee: PLURISTEM LTD.
    Inventor: Zami Aberman
  • Patent number: 10604738
    Abstract: This invention relates to the forward programming of pluripotent stem cells (PSCs) into megakaryocyte (MK) progenitor cells using the transcription factors GATA1, FLI1 and TAL1. Methods of producing megakaryocyte (MK) progenitor cells and subsequently differentiating them into mature megakaryocytes are provided.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: March 31, 2020
    Assignee: Cambridge Enterprise Limited
    Inventors: Roger Pedersen, Willem Ouwehand, Thomas Moreau, Cedric Ghevaert, Matthew Trotter
  • Patent number: 10577407
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 3, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • Patent number: 10576167
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 3, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10564149
    Abstract: A method of qualifying whether a cell population is a suitable therapeutic is disclosed. The method comprises: (a) incubating a population of undifferentiated mesenchymal stem cells (MSCs) in a differentiating medium comprising basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), heregulin and cAMP for at least two days to obtain a population of differentiated MSCs; and (b) analyzing the expression of CD49 a in the differentiated MSC population, wherein an amount of CD49 a above a predetermined level indicative of the cell population being suitable as a therapeutic.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: February 18, 2020
    Assignee: BrainStorm Cell Therapeutics Ltd.
    Inventors: Yael Gothelf, Yosef Levy
  • Patent number: 10563184
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: February 18, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Patent number: 10561688
    Abstract: The present invention relates to a method of preparing vascular endothelial cells by transforming (transdifferentiating) adult fibroblasts and a composition, which includes vascular endothelial cells prepared according to the method, for preventing and treating ischemic diseases, the method including a step of transducing adult fibroblasts with a gene. In particular, the present invention confirms that five factors, Foxo1, Er71, Klf2, Tal1, and Lmo2, induce transdifferentiation of adult fibroblasts into induced vascular endothelial cells. Furthermore, the present invention confirms that three factors, Er71, Klf2, and Tal1 induce transdifferentiation of human adult fibroblasts into induced vascular endothelial cells. The resultant induced endothelial cells enable lower limb salvaging by angiogenesis in lower limb ischemic animal models, showing that the induced endothelial cells can be effectively used for prevention or treatment of ischemic diseases.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 18, 2020
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Hyo-Soo Kim, Jung-Kyu Han, Sung-Hwan Chang, Hyun-Ju Cho, Saet-Byeol Choi, Youngchul Shin
  • Patent number: 10556953
    Abstract: The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: February 11, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventor: Hafid Ait-Oufella
  • Patent number: 10550183
    Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 4, 2020
    Assignee: National University of Singapore
    Inventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
  • Patent number: 10544394
    Abstract: The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and SDF-1 or analogues thereof. The present invention also relates to using such methods and compositions for ex vivo or in vivo bone formation in mammals.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: January 28, 2020
    Assignee: Mesoblast, Inc.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino
  • Patent number: 10538741
    Abstract: Novel adult liver progenitor cells (called H2Stem Cells) have been have been characterized on the basis of a series of biological activities and markers. Methods for producing H2Stem Cells allow providing such cells in the form of adherent cells and three-dimensional cell clusters in suspension that can be differentiated into cells having strong liver-specific activities and/or that can be used for treating liver diseases or for evaluating the efficacy, the metabolism, and/or toxicity of a compound.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: January 21, 2020
    Assignee: Promethera Biosciences S.A./N.V.
    Inventors: Etienne Sokal, Sarah Snykers, Tuba Baran, Kris Gellynck, Luca Falciola
  • Patent number: 10538568
    Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of FSHR. The invention provides novel peptides that specifically bind to Follicle-stimulation hormone receptor (FSHR).
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 21, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, Jr., Caitlin Stashwick, Katarzyna Urbanska
  • Patent number: 10517897
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 31, 2019
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10508289
    Abstract: The present invention is in the field of genetic editing tools and methods of genetic engineering. It relates to the engineering of rare-cutting endonucleases designed to contract highly repetitive motives in chromosomes, which are at the origin of certain genetic diseases, in particular the so-called “triplet repeat diseases”, such as the Huntington disease. The invention encompasses the method for contracting the repetitive motives, the rare-cutting endonucleases for use to contract repetitive motives in a gene subjected to repeat disorder, the polynucleotides and vectors encoding thereof as well as the resulting pharmaceutical compositions.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: December 17, 2019
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Alexandre Juillerat
  • Patent number: 10508263
    Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: December 17, 2019
    Assignee: Procella Therapeutics AB
    Inventors: Kenneth R. Chien, Jonathan Clarke, Miia Lehtinen, Kylie Foo, Chuen Yan Leung
  • Patent number: 10501519
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 10, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, John Scholler, Avery D. Posey, Jr.
  • Patent number: 10493109
    Abstract: The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 3, 2019
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Dongming Sun, Wise Young
  • Patent number: 10479821
    Abstract: Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: November 19, 2019
    Assignee: University of Washington
    Inventors: Jeffrey S. Chamberlain, Julian Ramos, Stephen D. Hauschka
  • Patent number: 10478526
    Abstract: This invention provides compositions in the form of skin substitutes comprising epithelial cells and mesenchymal cells, wherein the mesenchymal cells are not isolated from the occipital or nape region of the scalp, as well as methods for using the same.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: November 19, 2019
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Rajesh Thangapazham, Thomas N. Darling, Shaowei Li
  • Patent number: 10478457
    Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimerization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: November 19, 2019
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Ryan Trowbridge, Edward Hodgkin
  • Patent number: 10472686
    Abstract: Disclosed herein are methods and compositions for determining the presence or absence of a mechanism of antimicrobial resistance in a sample.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 12, 2019
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Diego Ariel Rey, Micah Bodner, Jeremiah Marsden
  • Patent number: 10457731
    Abstract: Nucleic acids that encode chemically-inducible fusion proteins, vectors that contain nucleic acids that encode chemically-inducible fusion proteins, chemically-inducible fusion proteins, chemically-inducible fusion protein complexes, and non-natural cells that are modified to express chemically-inducible fusion proteins to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 29, 2019
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo